Blog

Aug 26, 2026

Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes and produces gastrointestinal side effects in the majority of patients — primarily nausea, diarrhea, vomiting, and constipation — most prominently during dose escalation. These effects are dose-dependent and class-wide across all GLP-1 receptor agonists. In the SUSTAIN-1 trial, nausea occurred in approximately 15 to […]

Aug 18, 2026

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both weekly injectable GLP-1 receptor agonists used for weight management and metabolic disease, but they work through different mechanisms and produce substantially different outcomes. Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation, producing greater average weight loss (approximately 20% vs. 15% in head-to-head SURMOUNT-5 data), stronger glucose lowering, […]

Aug 10, 2026

Wegovy and Ozempic contain the same active ingredient — semaglutide — but they are different products with different FDA approvals, different doses, and critically different insurance coverage implications. Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management. Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes. Using one when you need the other […]

Aug 1, 2026

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes — not for weight loss. However, off-label prescribing for weight management is common in clinical practice, and the molecule’s weight loss data from the SURMOUNT trials (up to 20.2% body weight reduction) is among the strongest in obesity pharmacology. Zepbound is the same tirzepatide molecule with an […]

Jul 26, 2026

Compounded tirzepatide was legally available in the United States from 2022 to early 2025 during the FDA drug shortage period, but enforcement deadlines have since passed and routine compounding is no longer legally supported. The FDA resolved the tirzepatide shortage in December 2024 and set enforcement deadlines of February 19, 2025 for 503A pharmacies and […]

Jul 17, 2026

Compounded semaglutide is not FDA-approved and has not been evaluated for safety, potency, or sterility by the FDA. It was legally available during the period when semaglutide was on the FDA drug shortage list (2022 to 2025), allowing licensed compounding pharmacies to produce it under specific regulatory conditions. On February 21, 2025, the FDA issued […]

Jul 10, 2026

Wegovy (semaglutide 2.4mg) produces gastrointestinal side effects in the majority of patients, most commonly nausea, vomiting, diarrhea, and constipation. These occur predominantly during dose escalation and typically diminish at stable maintenance doses. In STEP-1, 44% of participants on Wegovy reported nausea vs. 16% on placebo, and 4.5% discontinued due to GI adverse events. Beyond GI […]

Jul 2, 2026

Retatrutide (LY3437943) is an investigational once-weekly injection from Eli Lilly that activates three metabolic receptors simultaneously — GIP, GLP-1, and glucagon — producing the highest average weight loss ever recorded in a Phase 3 clinical trial. In TRIUMPH-1 (May 2026), adults with obesity on the 12mg dose lost a mean of 28.3% of body weight […]

Jun 25, 2026

“Ozempic face” is the colloquial term for the facial volume loss and skin laxity that some patients experience during rapid weight loss on GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound). The phenomenon is not a side effect of the medication itself but a consequence of rapid fat loss, which depletes subcutaneous […]

Jun 15, 2026

Sermorelin is a 29 amino acid growth hormone-releasing hormone (GHRH) analogue administered as a nightly subcutaneous injection to stimulate the pituitary’s own growth hormone production. Standard starting doses range from 200 to 300 mcg per injection, titrated upward based on IGF-1 response and symptom assessment. Results are gradual: most patients notice improved sleep quality within […]

Jun 8, 2026

Sermorelin and human growth hormone (HGH) both raise growth hormone levels but through fundamentally different mechanisms, with different safety profiles, legal status, and cost implications. HGH is FDA-approved for specific growth hormone deficiency conditions and is a controlled substance requiring strict medical oversight. Sermorelin is a growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary […]

Jun 4, 2026

Testosterone replacement therapy suppresses sperm production in the majority of men, often to levels incompatible with natural conception. This effect is caused by the suppression of the hypothalamic-pituitary-gonadal (HPG) axis: exogenous testosterone shuts down the FSH and LH signals that drive spermatogenesis in the testes. The suppression is typically reversible after stopping TRT, but recovery […]